Form 4: Amylyx Pharmaceuticals Co-CEO Joshua Cohen Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- On February 3, 2025, Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, sold 11,851 shares of common stock.
- The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
- The shares were sold at a weighted average price of $3.4687, with individual transactions ranging from $3.46 to $3.58.
- Following the transaction, Cohen directly owns 3,201,247 shares of Amylyx Pharmaceuticals.
Sentiment
Score: 5
Explanation: The document describes a routine stock sale to cover tax obligations, which is neither particularly positive nor negative.
Industry Context
Form 4 filings are a routine part of the US stock market, and are required by the SEC to provide transparency when company insiders trade their own company's stock. It is important to note that this is not necessarily an indication of the company's performance or future prospects.
Key Dates
| Date | Description |
|---|---|
| 02/03/2025 | Date of stock sale transaction |
| 02/05/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.